203 related articles for article (PubMed ID: 14603339)
1. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Mishra S; Zhang B; Groffen J; Heisterkamp N
Leukemia; 2004 Jan; 18(1):23-8. PubMed ID: 14603339
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.
Nakajima A; Tauchi T; Sumi M; Bishop WR; Ohyashiki K
Mol Cancer Ther; 2003 Mar; 2(3):219-24. PubMed ID: 12657715
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.
Reichert A; Heisterkamp N; Daley GQ; Groffen J
Blood; 2001 Mar; 97(5):1399-403. PubMed ID: 11222386
[TBL] [Abstract][Full Text] [Related]
4. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
O'Dwyer M
Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
[TBL] [Abstract][Full Text] [Related]
5. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.
Kaur P; Feldhahn N; Zhang B; Trageser D; Müschen M; Pertz V; Groffen J; Heisterkamp N
Mol Cancer; 2007 Oct; 6():67. PubMed ID: 17958915
[TBL] [Abstract][Full Text] [Related]
6. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Williams RT; Sherr CJ
Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
[TBL] [Abstract][Full Text] [Related]
7. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
8. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
[TBL] [Abstract][Full Text] [Related]
9. The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
Brain J; Saksena A; Laneuville P
Leuk Res; 2002 Nov; 26(11):1011-6. PubMed ID: 12363470
[TBL] [Abstract][Full Text] [Related]
10. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
11. The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
Ottmann OG; Hoelzer D
Hematol J; 2002; 3(1):2-6. PubMed ID: 11960387
[No Abstract] [Full Text] [Related]
12. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a.
Zhang B; Groffen J; Heisterkamp N
Blood; 2005 Aug; 106(4):1355-61. PubMed ID: 15860663
[TBL] [Abstract][Full Text] [Related]
13. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
le Coutre P; Mologni L; Cleris L; Marchesi E; Buchdunger E; Giardini R; Formelli F; Gambacorti-Passerini C
J Natl Cancer Inst; 1999 Jan; 91(2):163-8. PubMed ID: 9923858
[TBL] [Abstract][Full Text] [Related]
14. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
[TBL] [Abstract][Full Text] [Related]
15. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
Hoover RR; Mahon FX; Melo JV; Daley GQ
Blood; 2002 Aug; 100(3):1068-71. PubMed ID: 12130526
[TBL] [Abstract][Full Text] [Related]
16. [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Thomas X
Bull Cancer; 2007 Oct; 94(10):871-80. PubMed ID: 17964981
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia.
Hallböök H; Barbany G; Aleskog A; Björnberg A; Larsson R; Sundström C; Lindhagen E
Anticancer Drugs; 2005 Jul; 16(6):631-4. PubMed ID: 15930891
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
von Bubnoff N; Veach DR; Miller WT; Li W; Sänger J; Peschel C; Bornmann WG; Clarkson B; Duyster J
Cancer Res; 2003 Oct; 63(19):6395-404. PubMed ID: 14559829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]